Allogene Therapeutics Inc (ALLO) concluded trading on Thursday at a closing price of $2.02, with 2.73 million shares of worth about $5.52 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -20.47% during that period and on December 12, 2024 the price saw a loss of about -5.61%. Currently the company’s common shares owned by public are about 209.50M shares, out of which, 142.62M shares are available for trading.
Stock saw a price change of -5.61% in past 5 days and over the past one month there was a price change of -28.87%. Year-to-date (YTD), ALLO shares are showing a performance of -37.07% which decreased to -14.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.99 but also hit the highest price of $5.78 during that period. The average intraday trading volume for Allogene Therapeutics Inc shares is 2.25 million. The stock is currently trading -10.66% below its 20-day simple moving average (SMA20), while that difference is down -21.31% for SMA50 and it goes to -31.56% lower than SMA200.
Allogene Therapeutics Inc (NASDAQ: ALLO) currently have 209.50M outstanding shares and institutions hold larger chunk of about 68.26% of that.
The stock has a current market capitalization of $423.54M and its 3Y-monthly beta is at 0.84. It has posted earnings per share of -$1.56 in the same period. It has Quick Ratio of 9.35 while making debt-to-equity ratio of 0.20. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALLO, volatility over the week remained 6.91% while standing at 7.37% over the month.
Stock’s fiscal year EPS is expected to rise by 36.46% while it is estimated to decrease by -1.47% in next year. EPS is likely to shrink at an annualized rate of 1.00% for next 5-years, compared to annual growth of 22.18% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on August 08, 2024 offering an Outperform rating for the stock and assigned a target price range of between $13 and $11 to it. Coverage by Piper Sandler stated Allogene Therapeutics Inc (ALLO) stock as an Overweight in their note to investors on May 31, 2024, suggesting a price target of $11 for the stock. Stock get a Buy rating from Citigroup on December 08, 2023.
